Introduction
Multiple myeloma (MM) is a B-cell malignancy characterized by the clonal proliferation of terminally differentiated plasma cells, monoclonal gammaglobulinemia, immunodeficiency, renal insufficiency and multiple bone lesions. 1, 2 Although high-dose chemotherapy induces complete remission in a small fraction of patients, long-term remission is rare. In addition, sufferers tend to belong to older age groups, which can limit the use of conventional chemotherapeutic agents due to complications. As a result, there is an urgent need for novel treatment modalities that are suitable even for high-risk patients.
The interaction between myeloma cells and bone marrow microenvironment has a key role in the pathogenesis of MM. 2, 3 These involve the production of cytokines and growth factors such as interleukin-6 (IL-6) and insulin-like growth factor-1, as well as physical interactions. IL-6 strongly promotes the cellular proliferation of myeloma cells, especially in the early stages of tumorigenesis. 3, 4 Myeloma cells produce several proangiogenic factors, including VEGF, fibroblast growth factor-2, angiopoietin-1, metalloproteinases and urokinase-type plasminogen activator. [5] [6] [7] Bone marrow angiogenesis has an important role in progression of MM: microvessel density and angiogenesis in the bone marrow are correlated with the prognosis and survival of MM patients. [5] [6] [7] Therefore, VEGF and its cognate receptor are both believed to be potential targets for antimyeloma treatment. Preclinical trials with VEGF-neutralizing antibodies have reported inhibition of the production of metalloproteinases, tumor necrosis factor-a and IL-1b in solid tumors 8 and myelomonocytic leukemia. 9 Moreover, VEGF receptor (VEGFR) tyrosine kinase inhibitor has been shown to suppress the proliferation and migration of myeloma cells expressing VEGFR-1 (Flt-1). 10 It is currently under a phase II study for the treatment of MM. 11 Thalidomide has been reported to inhibit the myeloma cell growth through induction of apoptosis and blockade of the interaction between myeloma cells and bone marrow stromal cells (BMSCs), 2 in addition to the antiangiogenic activity through inhibition on FGF-2 induced angiogenesis. 12 Thus, an antiangiogenic therapeutic strategy might be useful for the treatment of MM.
All-trans retinoic acid (ATRA) and other retinoids have been reported to inhibit the growth of a range of malignancies both in vitro and in vivo, including acute promyelocytic leukemia (APL), neuroblastoma, lung cancer and MM. [13] [14] [15] [16] [17] [18] ATRA induces cell differentiation, cell cycle arrest, apoptotic cell death, and IL-6/IL-6R downregulation in vitro. [16] [17] [18] Retinoids exert their effects through interactions with two types of nuclear receptors, retinoic acid receptor (RAR) and retinoid X receptor (RXR), each of which has three subtypes (-a, -b and -g). ATRA is one of the most clinically successful retinoids, however, its high rates of adverse effects, instability, and the appearance of ATRA-resistant leukemia cells have provided obstacles to ATRA-based therapies. 19 In an attempt to overcome these problems, Am80 has been synthesized by the introduction of heteroatoms into ATRA-like structures (Figure 1) . 20 Am80 is a RAR-a/b-selective retinoid, that does not bind and activate RARg and RXRs, hence can spare unfavorable adverse effects. Am80 has little affinity for cellular retinoic acid binding protein (CRABP) and is active against CRABP-rich ATRA-resistant cells. 21, 22 In addition, it is more stable against light, heat and oxidation than ATRA. Tobita et al reported that 14 out of 24 (58%) APL patients who relapsed after ATRA treatment showed complete remission by the treatment with Am80 and experienced fewer adverse side effects in clinical trials. 22 Thus, Am80 has additional therapeutic advantages compared with ATRA. Furthermore, Am80 has been shown to decrease IL-1-induced IL-6 production in vitro, 23 and inhibit angiogenesis in chicken chorioallantoic membranes. 24 However, there have been no further reports on the mechanisms of this antiangiogenic activity.
In this study, we therefore examined the inhibitory effects of Am80 on myeloma cell-induced angiogenesis.
Materials and methods

Cell lines and culture
The human myeloma cell lines, U266, AMO1, ILKM-2, ILKM-3 and ILKM-8, used in this study, were described previously. 25, 26 All cell lines were cultured in RPMI 1640 medium containing 10% fetal bovine serum (FBS), streptomycin, and penicillin. Recombinant human IL-6 (Diaclone research, Besancon, France) was added at 10 ng/ml to the medium of ILKM-2, ILKM-3 and ILKM-8. Human umbilical vein vascular endothelial cells (HUVECs) were purchased from Clonetics (Walkers Ville, MD, USA) and BMSCs cells were from Bio Whittaker (MD, USA) through Sanko Junyaku (Tokyo, Japan), and were cultured according to the manufacturer's instruction. NIH3T3/KDR and NIH3T3/Flt-1 cells, which were kindly provided by Dr M Shibuya (University of Tokyo, Tokyo, Japan), were cultured in DMEM supplemented with 10% FBS.
Materials
Am80 was kindly gifted by Dr H Kagechika (University of Tokyo, Tokyo, Japan). 27 ATRA was purchased from Sigma (St Louis, MO, USA). Chemical structures of Am80 and ATRA are presented in Figure 1 . Each retinoid was dissolved in dimethylsulfoxide at 10 mM. Human recombinant VEGF 165 was purchased from R&D Systems (Minneapolis, MN, USA). The selective VEGF receptor tyrosine kinase inhibitor, 3-[(2,4-dimetylpyrrol-5-yl) methylidenyl]-iodolin-2-one (SU5416) was provided by SUGEN 28 and the Taiho Pharmaceutical Co. (Tokyo, Japan).
Growth inhibition assay
The growth inhibitory effects of the retinoids for myeloma cell lines were determined using a methyl-thiazolyl tetrazolium (MTT) assay. Cells (2 Â l0 4 /well) were cultured in 96-well plates in triplicate with or without Am80, in a final volume of 100 ml at 371C for 48 h. After incubation, 10 ml of 5 mg/ml MTT solution (Sigma) was added to each well, the cells were incubated for 4 h at 371C, and 100 ml of lysis buffer (0.04 N HCl and isopropanol) was added. 
Enzyme-linked immunosorbent assay (ELISA) of VEGF for cocultured system
Myeloma cells (1 Â 10 5 ) were cultured at 371C in a final volume of 1 ml in culture medium. We used the conditioned medium for coculture migration assay after 48 h incubation and the concentration of VEGF was determined using commercially available ELISA kit (R&D systems).
Immunoblotting assay
NIH3T3/KDR and NIH3T3/Flt-1 cells were cultured in serumdepleted DMEM for 48 h and then cells were preincubated with Am80 for 12 h or SU5416
28-30 for 3 h followed by stimulation with 30 ng/ml VEGF for 5 min at 371C. After incubation, the cells were washed with cold-PBS (phosphate-buffered saline) and lysed in the buffer (50 mM HEPES, 150 mM NaCl, 1% Triton X-100, and 10% glycerol containing 1 mM PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin and 1 mM sodium vanadate). Cell lysates were subjected to SDS-PAGE and transferred to Immobilon membranes (Millipore, MA, USA). After transfer, membranes were incubated with the blocking solution and probed with antiphosphotyrosine (PY20), anti-KDR or anti-Flt-1 antibody (Santa Cruz Biotechnologies, CA, USA), antiphospho ERK1/2 or anti-ERK1/2, antiphospho Akt or anti-Akt antibody (Cell Signaling, MA, USA) followed by washing. The protein contents were visualized using horseradish peroxidase-conjugated secondary antibodies followed by enhanced chemiluminescence (ECL, Amersham/Pharmacia Biotech, NJ, USA).
Migration assay under coculture system
To assay for migration of HUVECs or BMSCs under coculture system, HUVECs or stromal cells were plated in the inner chambers after preincubation with or without Am80 or ATRA for 12 h or SU5416 for 3 h, and followed cocultivation with myeloma cells in the outer chambers (see Figure 2b ). HUVECs (3 Â 10 5 ) or stromal cells (3 Â 10 5 ) were suspended in medium and seeded in the inner chamber with polycarbonate filters (8 mm pores: Kurabo Inc., Tokyo, Japan) coated with human plasma fibronectin (1.33 mg/ml: Life Technologies, Inc., Tokyo, Japan). After 6 h (HUVECs) or 12 h (stromal cells) incubation at 371C, media in the inner chambers were aspirated, and cells on the upper surface of the filters were removed with a cotton swab. Cells on the lower surface of the filters were fixed with ethanol and stained with Giemsa, and the stained nuclei were counted. Five fields ( Â 100) per chamber were counted, and average numbers were determined with three chambers.
In vitro tube-formation assay
The effect of Am80 and ATRA on in vitro tube formation was assessed based on the VEGF-induced tube formation of HUVECs using an angiogenesis kit (Kurabo Industries Ltd, Tokyo, Japan) according to the manufacture's instructions. Briefly, cocultured HUVECs and fibroblasts were incubated with or without 10 ng/ ml VEGF and serial dilutions of Am80 or ATRA for 11 days. The medium containing VEGF and Am80 or ATRA was changed every 3 days. The wells were then fixed and immunostained with CD31, and the stained capillary structures in each well were photographed and quantified. Chemical structure of Am80 and ATRA.
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Mouse corneal micropocket assay and quantification of corneal neovascularization
A mouse corneal micropocket assay was performed as described previously. 29, 30 . Briefly, 0.3 ml of hydron pellets (IFN Sciences, NJ, USA) containing VEGF (200 ng/pellet) was implanted into the corneas of male BALB/c mice on day 1. Am80 was administered orally and SU5416 was administered intraperitoneally on days 0-6. All mice were killed on day 6 and their corneal vessels were photographed. Images of the corneas were recorded using Nikon Coolscan software (Nikon Corp., Tokyo, Japan) and corneal neovascularization was analyzed using the NIH Image 1.61 software package. 31 
Results
Migration of vascular endothelial cells cocultured with myeloma cells and inhibitory effect of Am80
We first examined the inducing effect of myeloma cells on migration of HUVECs. As shown in Figure 2a , five myeloma cell lines secreted varying amounts of VEGF into the culture medium during incubation for 48 h. We then examined if myeloma cells could stimulate migration of HUVECs under coculture assay condition (Figure 2b ). The migration of HUVECs to the lower surface of the filters was assayed after incubation for further 6 h. The results revealed that coculture with AMO1 or ILKM-8, 
to three-fold increase in migration compared with the control in the absence of myeloma cells (Figure 2c ). When cocultured with U266, ILKM-2 or ILKM-3, which produced less amount of VEGF than AMO1 or ILKM-8, migration of HUVECs showed much less increase. Remarkable cell migration of HUVECs was observed by exogenous addition of VEGF (20 ng/ml) in the outer chamber.
We then examined the inhibitory effect of Am80, ATRA and SU5416 on migration of HUVECs when cocultured with AMO1 or ILKM-8 cells. Chemical structures of Am80 and ATRA are shown in Figure 1 . Myeloma cell-induced migration of HUVECs was remarkably inhibited by Am80 at 10 mM (Figure 2d and e) . ATRA also showed the inhibitory effect at the similar levels to Am80, and SU5416, a selective VEGF receptor tyrosine kinase inhibitor, inhibited migration of HUVECs at 5 mM completely.
Growth inhibitory effect of Am80 on myeloma cells and HUVECs
We then examined if Am80 inhibited the growth of myeloma cells and HUVECs. Am80 at 10 mM showed a subtle inhibitory effect on the basal growth of myeloma cells and HUVECs (Figure 3a and b) . Mean of 50% inhibitory concentration (IC 50 ) values of Am80 were ranging from 20 to 30 mM. We also examined the growth inhibitory effect of Am80 on HUVECs under VEGF-stimulated condition (Figure 3c ). Exogenous addition of VEGF stimulated cell growth more than 1.5-fold over the control, and Am80 significantly inhibited VEGF-induced cellular growth of HUVECs (IC 50 values are 5 mM).
Am80 inhibits migration of BMSCs cocultured with myeloma cells
In order to understand if Am80 could modulate the microenvironment in multiple myeloma, we then examined the effect of Am80 on cell growth and migration of BMSCs. As shown in Figure 4a , Am80 up to 10 mM was found to show no inhibition on cell growth of BMSCs. Coculture with ILKM-8 or AMO1 stimulated migration of stromal cells two-to three-fold over the control, and Am80 inhibited myeloma cell-induced migration in a dose-dependent manner (Figure 4b ).
Am80 induces IL-6/IL-6R downregulation and cell cycle arrest in myeloma cell
We then examined the mechanism of the growth inhibitory effects of Am80 on myeloma cells (see Supplementary Information). The IL-6 production from U266 cells was decreased by the treatment of Am80 in a dose-dependent manner, and IL-6R expression on cell surface membrane of U266 and ILKM-2 cells was also downregulated by Am80 at 1 mM after 24 h. Regarding cell cycle progression, the number of cells at the G0/G1 phase was slightly increased, and that at the S and G2/M phases was reduced in both ILKM-2 and U266 cells after 24 h treatment with Am80 at 1 mM. We further examined the expression and phosphorylation of cell cycle-related proteins using immunoblotting. The levels of phosphorylated Rb markedly decreased 24 h after treatment with Am80 at 1 mM, and a slight increase in p21 levels was observed. Apoptotic changes were not observed (data not shown). 
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Effect of Am80 on VEGF-induced autophosphorylation of VEGF receptors
In order to understand the inhibitory mechanism of Am80 on VEGF-induced migration of HUVECs, we examined if Am80 could modulate VEGF-induced activation of two VEGF receptor molecules, VEGFR-1(Flt-1) and VEGFR-2(KDR). We could not detect any apparent expressions of both VEGFRs in HUVECs by immunoblotting, since the receptor numbers were very low. We therefore used Flt-1 or KDR overexpressing NIH3T3 cells. In these cells, immunoblotting with antiphosphotyrosine antibody indicated that Flt-1 and KDR were autophosphorylated in response to VEGF (Figure 5a ), consistent with our previous report. 30 Am80 significantly inhibited autophophorylation of Flt-1 at 0.1 mM, while Am80 inhibited that of KDR at 1 mM (Figure 5a ). SU5416 completely blocked autophosphorylation of both VEGFRs at 5 mM. We also examined the effect of Am80 on the downstream signaling molecules of VEGF receptors, Akt and ERK1/2 in HUVECs. We could detect apparent activation of Akt and ERK1/2 in response to VEGF in HUVECs (Figure 5b ). Phosphorylation of Akt was almost completely inhibited by Am80 at 10 mM. However phosphorylation of ERK1/2, however, was not inhibited by Am80 at 10 mM. By contrast, SU5416 at 5 mM almost completely inhibited phosphorylation of both Akt and ERK1/2. We also examined the effect of Am80 on VEGF production by myeloma cells, however, Am80 did not affect VEGF production (data not shown).
Effect of Am80 on VEGF-induced tube formation by vascular endothelial cells
We then examined if Am80 inhibited the formation of tube-like structures in vitro in response to VEGF using HUVECs. As shown in Figure 6A , 10 ng/ml of VEGF increased tube formation, whereas it was significantly inhibited by Am80 at 10 mM. Am80 did not show any cytotoxic effects even at a dose of 10 mM in this condition using confluent HUVECs. Quantitative analysis demonstrated that the rate of tube formation was two-fold higher in the presence of VEGF, but was inhibited by Am80 in a dose-dependent manner ( Figure 6B ). Am80 at 0.1 or 1 mM showed almost 40-50 or 50-60% inhibition, respectively. ATRA also inhibited tube formation ( Figure 6C ), but cytotoxic effect was detected at a dose of 10 mM (data not shown).
Am80 inhibits VEGF-induced neovascularization in the mouse cornea
We finally examined the in vivo effect of Am80 on VEGFinduced angiogenesis using a mouse corneal micropocket assay. VEGF (200 ng) in a hydron pellet-induced angiogenesis in the mouse cornea ( Figure 7A and B) . Oral administration of Am80 (10 mg/kg/day) significantly inhibited the VEGF-induced angiogenesis ( Figure 7A a-c) . Intrapenitonial administration of SU5416 (25 mg/kg/day) also inhibited VEGF-induced neovascularization consistent with our previous findings ( Figure 7A  d and B) .
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Discussion
In spite of a significant advancement in conventional chemotherapy and wider applicability of high-dose treatment with transplantation of hematopoietic stem cells, MM still remains incurable. 1, 2 It is recently reported that the interaction between myeloma cells and bone marrow microenvironment have crucial roles in the pathogenesis of MM, 2 and acquired drug resistance is also mediated by environmental factors. 32 Multiple myeloma cells could stimulate angiogenesis through paracrine control of VEGF and other proangiogenic factors. Therefore, we examined the myeloma cell-dependent angiogenesis and inhibitory effect of Am80 in vitro and in vivo.
Myeloma cell lines produced various amounts of VEGF, and cell migration of HUVECs was promoted by VEGF or coculture with myeloma cells (Figure 2 ). Am80 showed subtle (for myeloma cells and HUVECs) or little (for BMSCs) inhibitory effects on proliferation under basal condition (Figures 3 and 4a) . However, VEGF-induced proliferation of HUVECs was significantly inhibited by Am80 at 10 mM (Figure 3c ). Moreover, Am80 markedly inhibited migration of both HUVECs (Figure 2d and e) and BMSCs (Figure 4b ) when cocultured with myeloma cells. Am80 also blocked VEGF-induced formation of tube-like structures in vitro ( Figure 6 ) as well as neovascularization in mice corneas without cytotoxic effect (Figure 7 ). In addition, Am80 inhibited the phosphorylation of both VEGFR-1 and VEGFR-2 at similar levels as SU5416 ( Figure 5 ). Am80 did not affect VEGF production by myeloma cells under the coculture condition (data not shown). Although further investigation about the molecular mechanisms is necessary, these results demonstrated that Am80 has an inhibitory effect on VEGF-or myeloma cell-induced angiogenesis both in vitro and in vivo through downregulation of VEGF/VEGFR signaling. Therefore, Am80 is a potent inhibitor of this signaling, which might be a useful therapeutic agent against MM (Figure 8 ). VEGF-induced formation of tube-like structures and inhibitory effect of Am80. (A) The development of tube-like structures after 11 day's incubation in the absence or presence of VEGF (10 ng/ml); tube formation was significantly inhibited by Am80 at 10 mM without inhibition of cell viability. Quantitative analysis of the dose-dependent effect of Am80 (B) and ATRA (C). Tube formation was quantified as described in the Materials and methods. The results were shown as the mean7s.d. of triplicate analyses.
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Concerning the clinical use of retinoid for MM, several trials have been evaluated. Vesole et al (University of Arkansas) followed 11 MM patients receiving ATRA therapy, all of them were heavily pretreated and resistant to conventional chemotherapy (Vasole et al, personal communication). None of the patients achieved a complete or partial response (0%), one patient experienced stable disease (9%) and 10 patients were classified with progressive disease (91%). Koskela et al 33 also reported that ATRA alone is not effective to pretreated MM patients. These results were not satisfactory, however, all of the enrolled patients had heavily treated refractory myeloma, suggesting that tumor cells had lost their dependence of growth on IL-6. In this study, we observed the subtle inhibitory effect on myeloma cell growth through cell cycle arrest, as well as downregulation of IL-6/IL-6R (Figure 3a and Supplementary Information). IL-6/IL-6R signaling is much more important for the proliferation of early stage MM than refractory one.
1 Therefore, although both Am80 and ATRA do not have sufficient antitumor effect against cell lines or refractory MM, it is not possible to conclude that all types of retinoids will be ineffective against newly diagnosed or early stage MM. Furthermore, the pharmacological effects of retinoids are strongly affected by their chemical stability and by drug resistance in cancer cells. Serum level of Am80 was found to be more stable in patients than ATRA (unpublished data), and Am80 is characterized by a low potential for drug resistance, minimal adverse events and superior chemical stability. In highrisk patients, it is important that the risk of therapy-related mortality does not exceed the potential advantages of a treatment. Since Am80 appears to be the safe and practical agent, it could be used as the chemopreventive agents in combination with other chemotherapeutic or noncytotoxic agents for the indolent and smoldering types of myeloma cells, which do not necessarily need intensive chemotherapy and maintains the sensitivity to IL-6. In addition, it would be a suitable agent especially for the initially diagnosed MM in elderly, who cannot receive cytotoxic therapies. We have examined the synergistic inhibitory effect of Am80 on myeloma cell in combination with dexamethasone, and confirmed that Am80 possessed an additive effect on dexamethasone (data not shown).
Our results clearly show that Am80 has an inhibitory effect on angiogenesis induced by the interaction between vascular 
Figure 8
The scheme for inhibitory effects of Am80 on myeloma cell-induced angiogenesis. Multiple myeloma cells promote migration of vascular endothelial cells and angiogenesis through paracrine control of VEGF. Bone marrow stromal cells produce IL-6, which strongly stimulates cellular growth of myeloma cells. Am80 blocks myeloma cell-induced angiogenesis through inhibition of VEGFR phosphorylation. In addition, Am80 inhibits the expression of IL-6R on cell surface membrane of myeloma cells. endothelial cells and myeloma cells. On the basis of these findings, Am80 could be a promising clinical agent against MM.
